Share >  
Share
Share on Tumblr

Trileptal

News »

   latest by relevance
Glenmark expects interest costs to come down in Q3
Oct 30, 2009 at 14:02 | Source: Moneycontrol.com
Glenmark Pharmaceuticals declared its second quarter results for the financial year 2010. The companys Q2 consolidated net profit was down at Rs 80.9 crore versus Rs 117.3 crore and its consolidated net sales were up at Rs 590.3 crore versus Rs 559.7 crore
Expect FY10 topline to grow by 20-25%: Glenmark
Oct 29, 2009 at 15:43 | Source: CNBC-TV18
In an interview with CNBC-TV18, Glenn Saldanha, Managing Director and Chief Executive Officer, Glenmark Pharmaceuticals spoke about the companys results.
US biz contributed significantly to growth: Glenmark Pharma
Apr 28, 2008 at 14:15 | Source: CNBC-TV18
Glen Saldanha, MD & CEO of Glenmark Pharma said, one of the key factors for the outstanding numbers was a strong US business, which was driving growth and performance. Speaking to CNBC-TV18, he said that out-licensing of some of their NCE pipeline had also contributed significantly to the profits and topline sales.
Glenmark confirms ANDA filing for Tarka tablets
Dec 13, 2007 at 13:08
Glenmark Pharmaceuticals Limited, confirmed that Abbott (Abbott) filed suit on December 07, 2007 in the U.S. District Court for the District of New Jersey, seeking to prevent Glenmark from proceeding with the commercialization of its TRANDOLAPRIL; VERAPAMIL HYDROCHLORIDE products which is currently marketed by Abbott as Tarka
Taro results better due to low base: Sun Pharma
Dec 07, 2007 at 15:21 | Source: CNBC-TV18
Dilip Sanghavi CMD, Sun Pharma said, in an exclusive interview with CNBC-TV18, that Taro results are better due to low base. He added that they do not see the rationale for raising the bid price for Taro. The company has not seen any significant market share gain in Trileptal. The generic Effexor XR will be launched immediately upon approval.
Sun Pharmas net sales growth 25%, Net profit up 17%
Oct 26, 2007 at 13:25
Sun Pharmas net sales growth 25%, Net profit up 17%; R&D spend at Rs 713 mill

Videos »
Expect FY10 topline to grow by 20-25%: Glenmark
US biz contributed significantly to growth: Glenmark Pharma
Taro results better due to low base: Sun Pharma
more »

Photos »

  /  
Related News »
Even as UCB’s Keppra Captures the Largest Patient Share, Followed by GSK’s Lamictal, Strong Company Support and Positive
UCB’s Vimpat, on the market for just over three years, captures 8 percent patient share — on par with more established AEDs, such as Novartis’ Trileptal, UCB’s Keppra XR and Abbott’s Depakote. Although only commercially available for ...
May 16, 2012 at 14:05 | Source: Bloomberg
Alabama doctor held responsible for wrongful death of patient
According to the Alabama lawsuit against the doctor, the patient who died in this case was prescribed the following prescription drugs: Valium, Xanax, Xanaflex, hydrocodone, trileptal, Demerol and Phenergan. The last two listed were to be administered ...
May 15, 2012 at 14:21 | Source: jdsupra.com

Follow moneycontrol.com

Facebook Twitter Google Plus RSS Wap SMS SMS Alert iPad iPhone Blackberry OVI Android Window